Table 1 |
||||||||
|
Patient demographics and clinical characteristics. |
||||||||
|
Patient number |
Sex |
Diagnosis |
Site involvement |
Reason for inclusión |
ANA/dsDNAα antibodies |
Anti-Ro/SSA/La/SSB antibodies |
CLASI A/D |
Previous received treatment |
|
|
||||||||
|
1 |
F |
DLE (L) |
V-neck, arm |
T lack of efficacy, PN |
1/640 (123) |
+/- |
6/2 |
TCS, OCS, HCQ, T |
|
2 |
F |
Lupus Profundus |
Arm, back |
T lack of efficacy |
1/160 (-) |
-/- |
7/1 |
TCS, OCS, HCQ, T |
|
3 |
F |
DLE (L) |
Arm |
T lack of efficacy |
1/640 (-) |
-/- |
3/1 |
TCS, OCS, HCQ, T |
|
4 |
F |
ACLE |
Face, v-neck |
T side effects |
1/640 (54) |
-/- |
6/0 |
TCS, OCS, HCQ, T, AZA, |
|
5 |
F |
Lupus Profundus |
Scalp, face, arms |
T side effects |
1/640 (144) |
-/- |
19/6 |
TCS, OCS, HCQ, MMF, T |
|
6 |
F |
SCLE |
Face, v-neck, back |
> 18% body surface |
1/640 (-) |
+/- |
19/0 |
TCS, OCS, MMF |
|
7 |
F |
SCLE |
Face, v-neck, hands, arms |
T side effects, PN, > 18% body surface |
1/640 (83) |
-/- |
20/1 |
TCS, OCS, HCQ, AZA, T |
|
8 |
F |
DLE (L) |
Face, scalp, ear lobe |
T side effects |
1/40 (-) |
-/- |
9/0 |
TCS, OCS, HCQ, T |
|
9 |
F |
DLE (G) |
Face, ear lobe, arms, neck |
> 18% body surface, T side effects |
1/320 (37) |
-/- |
13/2 |
TCS, OCS, HCQ, MMF, T |
|
10 |
F |
LET |
Face |
T side effects, PN |
1/640 (-) |
-/- |
6/0 |
TCS, HCQ, T |
|
11 |
F |
DLE (G) |
Face, scalp, back |
T side effects, > 18% body surface |
1/40 (-) |
+/- |
15/9 |
TCS, OCS, HCQ, T |
|
12 |
F |
DLE (G) |
Face, v-neck, back, scalp |
T side effects, PN |
1/40 (-) |
+/- |
17/8 |
TCS, OCS, HCQ, T |
|
13 |
F |
DLE (L) |
Face |
T lack of efficacy |
1/160 (-) |
-/- |
3/0 |
TCS, HCQ, T |
|
14 |
F |
DLE (G) |
Face, v-neck |
T side effects |
1/640 (-) |
-/- |
11/2 |
TCS, OCS, HCQ, MMF, T |
|
15 |
F |
DLE (L) |
Face, scalp |
T side effects |
1/40 (-) |
-/- |
10/3 |
TCS, OCS, HCQ, T |
|
|
||||||||
|
αNormal value of anti-dsDNA antibodies is < 15 IU/ml. A, activity; ACLE, acute cutaneous lupus erythematosus; ANA, antinuclear antibodies; AZA, azathioprine; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; D, damage; DLE, discoid lupus erythematosus; G, generalized; HCQ, hydroxychloroquine; L, localized; LET, lupus erythematosus tumidus; MMF, mycophenolate mofetil; OCS, oral corticosteroids; PN, polyneuropathy; SCLE, subacute cutaneous lupus erythematosus; T, thalidomide; TCS, topical steroids. |
||||||||
|
Cortés-Hernández et al. Arthritis Research & Therapy 2012 14:R265 doi:10.1186/ar4111 |
||||||||
